ReviewInflammopharmacology2026
NLRP3 Inflammasome Inhibitors as Precision Anti-inflammatory Pharmacotherapy: Translational Advances, Clinical Evidence, and Disease-specific Challenges.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting the NLRP3 inflammasome in immune cells: A new frontier in autoimmune disease research.Journal of translational autoimmunity · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome is pivotal ininnate immunity and inflammatory disease pathogenesis, notably through interleukins (IL)-1β and IL-18 and by triggering gasdermin D (GSDMD)-mediated pyroptosis. It has been implicated in cardiometabolic, renal, neuroinflammatory, and immune-mediated diseases, making NLRP3 a potential target for selective anti-inflammatory therapy. Clinical efficacy may vary according to disease biology, degree of NLRP3 inhibition, tissue distribution, and patient selection. This review covers the pharmacological and translational research of development of NLRP3 inhibitors and it summarizes the emerging clinical evidences from databases like PubMed, Scopus, Web of Science, Embase and ClinicalTrials.gov. It discusses several direct small-molecule NLRP3 inhibitors, including dapansutrile and selnoflastand others, including upstream activation mechanisms and downstream inflammatory mediators. Pharmacologic selectivity, potency, tissue distribution, activation of NLRP3 and clinical efficacy are among the key factors to consider in anti-inflammatory drug development. The success of these drugs in current use is variable, depending on the inflammatory type of the disease and the first generation of these drugs has shown liver toxicity. The role of the inflammasome in these conditions further supports the need for targeting NLRP3, especially in diseases such as cardiometabolic, renal and neuroinflammatory, but there are still hurdles to overcome, such as patient stratification and validation of biomarkers. Biomarker enriched populations should be targeted as a next step to improve the effectiveness of selective NLRP3 inhibition over current therapies.
Indexed as
Identifiers
42801391What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.